Drug intelligence / Profile preview

CS17919

Development stage: Unknown
Lead developer: Akeso
Modality: Small Molecules
Administration: Oral

Overview

CS17919 is a small molecule histone deacetylase (HDAC) inhibitor being developed by Chipscreen NewWay, a subsidiary of Shenzhen Chipscreen Biosciences. As an epigenetic modulator, it targets HDAC enzymes to increase the acetylation levels of histones and other cellular proteins, thereby regulating gene expression and inducing anti-tumor effects such as cell cycle arrest and apoptosis. The compound is specifically being investigated for the treatment of various hematological malignancies and is currently in Phase 1 clinical development.

Targets

MAP3K5 (ASK1)

Beyond the preview

Go deeper on CS17919.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS17919.

Explore the full profile